Analyst Reco. Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:00:02 15/12/2025 GMT			5-day change	1st Jan Change
318.80 ^DKK	-0.73%		+3.73%	-48.55%

07:44am	Kepler Cheuvreux lowers its target price for Novo Nordisk to DKK 430 (510), reiterates buy recommendation	FW
12-12	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Analyst Reco.

Kepler Cheuvreux lowers its target price for Novo Nordisk to DKK 430 (510), reiterates buy recommendation	07:44am	FW
Novo Nordisk faces limited risk from Lilly's Retatrutide	12-12
Nykredit lowers target price for Novo Nordisk to 400 Danish kroner (450), reiterates buy - BN	12-12	FW
NOVO NORDISK : Deutsche Bank reiterates its Buy rating	12-12	ZD
NOVO NORDISK : UBS reaffirms its Neutral rating	12-12	ZD
SEB Predicts Negative Organic Growth for Novo Nordisk Next Year, Lowers Target Price	12-11	FW
Ålandsbanken: SAFE Drugs Act may be positive for Novo Nordisk	12-11	FW
SEB Lowers Novo Nordisk Target Price to 440 Danish Kroner, Reiterates Buy	12-11	FW
HSBC Raises Price Target for Novo Nordisk to 350 Danish Kroner, Maintains Hold Rating	12-10	FW
NOVO NORDISK : Goldman Sachs keeps its Buy rating	12-09	ZD
NOVO NORDISK : JP Morgan gives a Buy rating	12-08	ZD
Novo Nordisk Kept at Buy as Berenberg Notes Obesity Market Focus, FY26 Headwinds	12-08	MT
JP Morgan Lowers Price Target for Novo Nordisk to 350 Danish Kroner (from 500), Maintains Overweight Rating - BN	12-08	FW
Berenberg Says Novo Nordisk Deserves Higher Valuation, Shares Rise - BN	12-05	FW
NOVO NORDISK : Berenberg gives a Buy rating	12-05	ZD
NOVO NORDISK : UBS reaffirms its Neutral rating	12-04	ZD
UBS Lowers Price Target for Novo Nordisk to 295 Danish Kroner, Reiterates Neutral Rating	12-04	FW
AstraZeneca Remains Top Pick at Morgan Stanley - BN	12-03	FW
Morgan Stanley Lowers Price Target for Novo Nordisk to 270 Danish Kroner, Reiterates Underweight Rating - BN	12-03	FW
BNP Paribas Exane Lowers Price Target for Novo Nordisk to 302 Danish Kroner (315), Reiterates Neutral Rating - BN	12-03	FW
Bank of America Raises Target Price for Novo Nordisk to 340 Danish Kroner, Maintains Neutral Rating	12-01	FW
NOVO NORDISK : UBS reiterates its Neutral rating	12-01	ZD
Jefferies Resumes Coverage of Novo Nordisk with Underperform Rating and Price Target of 270 Danish Kroner (290)	12-01	FW
NOVO NORDISK : Jefferies remains a Sell rating	12-01	ZD
NOVO NORDISK : Barclays gives a Neutral rating	11-28	ZD